source
- Perioperative Durvalumab Plus Neoadjuvant EV Displays EFS, OS Benefits vs SOC in MIBCPerioperative durvalumab plus EV showed positive topline efficacy findings in MIBC.onclive · 2mo ago↗ source
- Rintatolimod Plus Pembrolizumab and Cisplatin Displays 50% ORR in Recurrent Ovarian CancerThe addition of rintatolimod to pembrolizumab and cisplatin demonstrated robust albeit preliminary antitumor activity in patients with recurrent ovarian cancer.onclive · 2mo ago↗ source
- Create Medicines raises $122M to bolster in vivo CAR-T therapiesThe fresh funds will support the biotech's pipeline of RNA-based CAR-T cell therapies for cancer and autoimmune conditions.BioPharma Dive · 2mo ago